11/02/2026
Tremhance: A trial investigating a a new medicine (SAR448851) in people with early Alzheimer’s disease
What is the aim of the study?
This study is testing a new medicine called SAR448851 to see if it can slow down or slow the progression of early Alzheimer's disease (AD). Alzheimer's disease is a brain condition that causes memory loss, thinking problems, and difficulties with daily activities, affecting millions of people worldwide.
SAR448851 works by helping a protein in the brain called TREM2. TREM2 helps the brain clean away harmful substances that can build up and cause problems. Some people have changes in the TREM2 gene that make them more likely to develop Alzheimer's disease. Early studies suggest that helping TREM2 work better may protect the brain and reduce damage caused by Alzheimer's disease.
Find a clinical trial Tremhance: A trial investigating a a new medicine (SAR448851) in people with early Alzheimer’s disease Last updated 20 October 2026 Status Open Phase 2 Contact The Clinical Trial Finder is for information only. To join a clinical trial you must meet the eligibility criteria s...